IL1B and diabetes mellitus: Hence, IL-1β blockers in DCM are still in their infancy and may represent a unique opportunity to quench the inflammatory response following DM by selectively inhibiting a single apical mediator in the cascade, especially for patients with DCM combined with chronic inflammatory diseases.